Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shattuck LabsSTTK +4.80%42 3-Year ROIIC % is -348.07 as of Dec. 2025. GuruFocus rates STTK with a GF Score™ of 42/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,322 Biotechnology companies, Shattuck Labs ranks worse than 85.63% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Shattuck Labs's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -348.07%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Shattuck Labs's 3-Year ROIIC % or its related term are showing as below:
STTK's 3-Year ROIIC % is ranked worse than 85.63% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs STTK: -348.07
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Shattuck Labs 3-Year ROIIC % Related Terms
Shattuck Labs 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Shattuck Labs's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STTK vs ACHV, CRMD, EIKN: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Shattuck Labs's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shattuck Labs 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shattuck Labs's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Shattuck Labs's 3-Year ROIIC % falls into.
Shattuck Labs's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -51.508 (Dec. 2025) - -103.329 (Dec. 2022) )
/
( 12.391 (Dec. 2025) - 27.279 (Dec. 2022) )
=
51.821
/
-14.888
=
-348.07%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Shattuck Labs (STTK) has a 3-Year ROIIC % of -348.07 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shattuck Labs and its competitors. According to the industry distribution chart, Shattuck Labs ranks #1132 out of 1322 companies in the Biotechnology industry, placing it in the top 85.6%.
Is Shattuck Labs' 3-Year ROIIC % too high?
Shattuck Labs' current 3-Year ROIIC % is -348.07. Based on the distribution chart, Shattuck Labs ranks #1132 out of 1322 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shattuck Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shattuck Labs' 3-Year ROIIC % compare to ACHV and CRMD?
According to the Biotechnology industry distribution chart, Shattuck Labs ranks #1132 out of 1322 companies for 3-Year ROIIC %. This places Shattuck Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shattuck Labs and its competitors. Shattuck Labs's current 3-Year ROIIC % is -348.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shattuck Labs stock overvalued right now?
Based on GuruFocus' analysis, Shattuck Labs (STTK) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $7.42 — trading 606.7% above its estimated fair value. The current 3-Year ROIIC % is -348.07. Shattuck Labs' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Shattuck Labs (STTK), the current 3-Year ROIIC % is -348.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shattuck Labs (STTK) Overvalued in 2026?
Based on GuruFocus' analysis, Shattuck Labs stock appears to be overvalued.
The current stock price of $7.42 is trading 606.7% above its estimated GF Value™ of $1.05.
GuruFocus considers Shattuck Labs to be Significantly Overvalued.
Key valuation signals for STTK:
3-Year ROIIC %: -348.07
GF Value™: $1.05 vs. price of $7.42 (606.7% above fair value)
No single metric tells the full story. See the STTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
42GF Score
Get the complete analysis for STTK
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STTK has been successfully added to your 
